Alto Neuroscience Inc.
Symbol: ANRO (NYSE)
3.97
▲ (11.52%) 0.410
Company Description:
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
Key Stats
- Today's Open: $3.66
- Today's High: $3.97
- Today's Low: $3.48
- Today's Volume: 83.59K
- Yesterday Close: $3.56
- Yesterday High: $3.75
- Yesterday Low: $3.5
- Yesterday Volume: 76.45K
- Last Min Volume: 103
- Last Min High: $3.97
- Last Min Low: $3.97
- Last Min VWAP: $3.97
Company Profile
- Name: Alto Neuroscience Inc.
- Website: https://www.altoneuroscience.com
- Listed Date: 2024-02-02
- Location: MOUNTAIN VIEW, CA
- Market Status: Active
- CIK Number: 0001999480
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $96.39M
- Round Lot: 100
- Outstanding Shares: 27.08M
- Asset Type: CS
RECENT FILINGS FOR ANRO
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | 4 | View |
| 2025-08-14 | 3 | View |
| 2025-08-13 | 10-Q | View |
| 2025-08-13 | 8-K | View |
| 2025-07-16 | SCHEDULE 13G/A | View |
| 2025-07-08 | 4 | View |
| 2025-07-08 | 4 | View |
| 2025-07-08 | 4 | View |
| 2025-07-08 | 4 | View |
| 2025-07-08 | 8-K | View |
| 2025-06-26 | 8-K | View |
| 2025-06-03 | 8-K | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-15 | 4 | View |
| 2025-05-15 | 4 | View |
| 2025-05-15 | 4 | View |
| 2025-05-15 | 4 | View |
| 2025-05-15 | SCHEDULE 13G | View |
| 2025-05-15 | SCHEDULE 13G | View |
Latest News on ANRO